Portal hypertension management sales will grow through 2036, led by drug class treatments at 41.8% of the treatment segment in 2026. The market was valued at USD 3.36 billion in 2025 and is expected to be worth USD 5.63 billion by 2036, creating an incremental opportunity of USD 2.11 billion.